1,1'-azobis(N,N-dimethylformamide) profile

1,1'-Azobis(N,N-dimethylformamide) (ABDF) is a versatile azo-initiator widely employed in free-radical polymerization reactions. It decomposes upon heating, generating free radicals that initiate chain polymerization processes. ABDF's decomposition temperature is relatively low, making it suitable for polymerization reactions conducted at moderate temperatures. The compound is commonly used in the synthesis of polymers, such as poly(methyl methacrylate) (PMMA) and poly(vinyl chloride) (PVC). Its effectiveness as an initiator is attributed to the stability of its azo group and the ease with which it can generate free radicals. ABDF's versatility has also led to its use in other applications, including grafting reactions, cross-linking of polymers, and the production of nanocomposites. Research on ABDF often focuses on optimizing its performance as an initiator, understanding its decomposition mechanism, and exploring new applications in various fields.'

ID Source	ID
PubMed CID	4278
CHEMBL ID	1338900

Synonym
MLS002153343
smr000326672
LOPAC0_000397
HMS2234I06
FT-0636707
LP00397
1,1'-azobis (n,n-dimethyl-formamide)
n,n,n',n'-tetra-methylazodicarboxamide
n1,n1,n2,n2-teramethyldiazene-1,2-dicarboxamide
VLSDXINSOMDCBK-UHFFFAOYSA-N
n,n,n',n'-tetramethylazo-dicarboxamide
n,n,n',n'-tetramethyl azodicarboxamide
n,n,n',n'-tetra methyl azodicarboxamide
1,1'-azobis(n,n'-dimethylformamide)
CHEMBL1338900
n,n,n inverted exclamation mark ,n inverted exclamation mark -tetramethylazodicarboxamide(tmad)
SY001003
c6h12n4o2
DTXSID6040456
AKOS028108436
Q4381023
Q27121402
(e)-n1,n1,n2,n2-tetramethyldiazene-1,2-dicarboxamide
n,n,n`,n`-tetramethylazodicarboxamide(tmad)

Class	Description
monoazo compound	Compounds containing single -N=N- group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	89.1251	0.0447	17.8581	100.0000	AID485294
ATAD5 protein, partial	Homo sapiens (human)	Potency	35.4813	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	14.8981	0.0008	11.3822	44.6684	AID686978; AID686979
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	50.1187	0.1000	22.9075	100.0000	AID485364
hypothetical protein, conserved	Trypanosoma brucei	Potency	6.3096	0.2239	11.2451	35.4813	AID624173
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	70.7946	0.5318	15.4358	37.6858	AID504845
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	2.2387	0.0355	20.9770	89.1251	AID504332
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	19.9526	0.3548	28.0659	89.1251	AID504847
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	1.8888	0.1683	16.4040	67.0158	AID720504
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	25.1189	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	0.6310	0.0046	11.3741	33.4983	AID624297
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	12.5960	0.0601	10.7453	37.9330	AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	2 (25.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

1,1'-azobis(N,N-dimethylformamide)

Cross-References

Synonyms (24)

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Bioassays (16)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.17

Study Types

1,1'-azobis(N,N-dimethylformamide)

Cross-References

Synonyms (24)

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Bioassays (16)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.17

Study Types

Related Conditions (6)